Directed new share issue in IRLAB Therapeutics AB (SE) — SEK 215 million

Carnegie acted as sole financial adviser in the capital raise of SEK 215 million. The company has resolved to carry out a directed issue of new shares of series A of approximately SEK 70 million to institutional and qualified investors  and a new issue of shares of series A of approximately SEK 145 million with pre-emptive rights for IRLAB’s shareholders. IRLAB is a Swedish biotech company focused on Parkinson’s disease. February 2020.